Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

被引：0
|
作者：
Eberhardt, W. E. E. [1 ]
Johnson, B. E. [2 ]
Sun, Y. [3 ]
Germonpre, P. [4 ]
Saijo, N. [5 ]
Zhou, C. [6 ]
Wang, J. [7 ]
Tada, H. [8 ]
Kennedy, S. [9 ]
Herbst, R. S. [10 ]
机构：
[1] Univ Duisburg Essen, German Tumor Ctr, Essen, Germany
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Canc Hosp, Beijing, Peoples R China
[4] Univ Antwerp Hosp, Antwerp, Belgium
[5] Natl Canc Ctr Hosp E, Chiba, Japan
[6] Tongji Univ, Shanghai 200092, Peoples R China
[7] Beijing Inst Canc Res, Beijing, Peoples R China
[8] AstraZeneca, Med Sci, Wilmington, DE USA
[9] AstraZeneca, Biostat, Macclesfield, Cheshire, England
[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71714-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：505 / 505
页数：1
相关论文
共 50 条
  • [1] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [2] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC)
    Herbst, Roy S.
    Sun, Yan
    Korfee, Soenke
    Germonpre, Paul
    Saijo, Nagahiro
    Zhou, Caichun
    Wang, Jie
    Langmuir, Peter
    Tada, Hiroomi
    Kennedy, Sarah J.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S357 - S358
  • [4] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    Herbst, Roy S.
    Sun, Yon
    Eberhardt, Wilfried E. E.
    Germonpre, Paul
    Saijo, Nagahiro
    Zhou, Caicun
    Wang, Jie
    Li, Longyun
    Kabbinavar, Fairooz
    Ichinose, Yukito
    Qin, Shukui
    Zhang, Li
    Biesma, Bonne
    Heymach, John V.
    Langmuir, Peter
    Kennedy, Sarah J.
    Tada, Hiroomi
    Johnson, Bruce E.
    LANCET ONCOLOGY, 2010, 11 (07): : 619 - 626
  • [5] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
    de Boer, Richard H.
    Arrieta, Oscar
    Yang, Chih-Hsin
    Gottfried, Maya
    Chan, Valorie
    Raats, Johann
    de Marinis, Filippo
    Abratt, Raymond P.
    Wolf, Juergen
    Blackhall, Fiona H.
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1067 - 1074
  • [6] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    De Boer, R.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    Vansteenkiste, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.
    Hosomi, Yukio
    Yoh, Kiyotaka
    Kasahara, Kazuo
    Yamada, Kazuhiko
    Takahashi, Toshiaki
    Tanaka, Kaoru
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Kato, Terufumi
    Takeda, Koji
    Nishio, Makoto
    Sakai, Hiroshi
    Maemondo, Makoto
    Takenoyama, Mitsuhiro
    Nokihara, Hiroshi
    Tatsumi, Masumi
    Nakamura, Takashi
    Enatsu, Sotaro
    Tamura, Tomohide
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial
    Georgoulias, V
    Ardavanis, A
    Agelidou, A
    Agelidou, M
    Chandrinos, V
    Tsaroucha, E
    Toumbis, M
    Kouroussis, C
    Syrigos, K
    Polyzos, A
    Samaras, N
    Papakotoulas, P
    Christofilakis, C
    Ziras, N
    Alegakis, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2602 - 2609
  • [9] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [10] Cisplatin plus docetaxel as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)
    Doria, Simona
    Prochilo, Tiziana
    Cafferata, Mara Argenide
    Tiseo, Marcello
    Ardizzoni, Andrea
    Baldini, Editta
    ANNALS OF ONCOLOGY, 2007, 18 : 28 - 29
12345